Get the Stockscreener App
328.81
0.25%
0.81
After Hours:
328.81
Alnylam Pharmaceuticals Inc stock is traded at $328.81, with a volume of 666.67K.
It is up +0.25% in the last 24 hours and up +2.13% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$328.00
Open:
$331.5
24h Volume:
666.67K
Relative Volume:
0.72
Market Cap:
$42.87B
Revenue:
$2.35B
Net Income/Loss:
$-269.70M
P/E Ratio:
-157.33
EPS:
-2.09
Net Cash Flow:
$-75.39M
1W Performance:
+2.58%
1M Performance:
+2.13%
6M Performance:
+17.95%
1Y Performance:
+38.23%
1-Day Range:
$324.55
$331.50
1-Week Range:
$320.18
$332.19
52-Week Range:
$205.87
$333.70
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
How does Alnylam Pharmaceuticals Inc. compare to its industry peersDiscover undervalued stocks before they soar - jammulinksnews.com
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyMaximize gains with proven stock analysis - jammulinksnews.com
What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsUncover the best stocks for explosive growth - jammulinksnews.com
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Overwhelming financial success - jammulinksnews.com
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyInvest smarter with data-backed trading alerts - jammulinksnews.com
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthInvest in stocks with strong fundamentals - jammulinksnews.com
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionFree Market Analysis Group - Metal.it
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - Yahoo Finance
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
What drives Alnylam Pharmaceuticals Inc. stock priceDynamic investment growth - PrintWeekIndia
What analysts say about Alnylam Pharmaceuticals Inc. stockSuperior profit margins - PrintWeekIndia
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Benzinga
Huntington's Disease Clinical, Companies, Therapeutic - openPR.com
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
Alnylam Pharmaceuticals Surges to Top 277 Most Actively Traded Stocks with $412 Million in Trading Volume Following FDA Approval of Patisiran - AInvest
Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛
Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
10 Most Undervalued Healthcare Stocks to Buy According to Analysts - Insider Monkey
Lexicography: Clear And Unequivocal - The National Law Review
Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Canada
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail
Alnylam Pharmaceuticals’ Phase 2 Trial: A Potential Breakthrough in Cerebral Amyloid Angiopathy Treatment - TipRanks
Alnylam’s ALN-4324: A Promising Step in Obesity Treatment - TipRanks
Alnylam’s HELIOS-A Study: A Promising Update for hATTR Amyloidosis Treatment - TipRanks
Alnylam Pharmaceuticals stock price target raised to $290 by Cantor Fitzgerald - Investing.com Canada
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):